Controversies in HIV-associated neurocognitive disorders

The Lancet Neurology

Volumn 13, Issue 11, 2014, Pages 1139-1151

  Nightingale, Sam ^a   Winston, Alan ^b   Letendre, Scott ^c   Michael, Benedict D ^a,d   McArthur, Justin C ^e   Khoo, Saye ^a   Solomon, Tom ^a,d  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; VIRUS RNA;

ANTIVIRAL THERAPY; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID ANALYSIS; CLINICAL DECISION MAKING; COGNITION; COGNITIVE DEFECT; COMORBIDITY; COMPARATIVE EFFECTIVENESS; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DRUG EFFICACY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NEUROTOXICITY; PREVALENCE; REVIEW; VIRUS RESISTANCE; AIDS DEMENTIA COMPLEX; BLOOD; COGNITION DISORDERS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; METABOLISM; PROCEDURES;

AIDS DEMENTIA COMPLEX; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HIV-1; HUMANS; RNA, VIRAL;

EID: 84908006404     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70137-1     Document Type: Review

References (111)

1. Global HIV/AIDS response: epidemic update and health sector progress towards universal access. Progress report 2011 WHO, UNAIDSUNAIDS, UNICEFUNICEF, (accessed Oct 12 2012). http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf.
2. HIV in the United Kingdom: 2011 report. In: London: Health Protection Services Colindale Health Protection Agency, (accessed Dec 30 2012). http://www.hpa.org.uk/webc/hpawebfile/hpaweb_c/1317131685847.
3. van Sighem AI, Gras LA, Reiss P, Brinkman K, de Wolf F Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals. AIDS 2010, 24:1527-1535.
4. McArthur JC, Steiner J, Sacktor N, Nath A Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010, 67:699-714.
5. Grant I, Atkinson JH, Hesselink JR, et al. Evidence for early central nervous system involvement in the acquired immunodeficiency syndrome (AIDS) and other human immunodeficiency virus (HIV) infections. Studies with neuropsychologic testing and magnetic resonance imaging. Ann Intern Med 1987, 107:828-836.
6. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000, 69:376-380.
7. Letendre S, Ellis RJ, Deutsch R, et al. Correlates of time-to-loss-of-viral-response in CSF and plasma in the CHARTER cohort. 17th Conference on Retroviruses and Opportunistic Infections; San Fransisco, CA, USA; 2010. 430.
8. Rawson T, Muir D, Mackie NE, Garvey LJ, Everitt A, Winston A Factors associated with cerebrospinal fluid HIV RNA in HIV infected subjects undergoing lumbar puncture examination in a clinical setting. J Infect 2012, 65:239-245.
9. Eden A, Fuchs D, Hagberg L, et al. HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010, 202:1819-1825.
10. Heaton RK, Grant I, Butters N, et al. The HNRC 500-neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc 1995, 1:231-251.
11. Heaton RK, Franklin DR, Ellis RJ, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol 2011, 17:3-16.
12. Heaton RK, Clifford DB, Franklin DR, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology 2010, 75:2087-2096.
13. Wright EJ, Nunn M, Joseph J, Robertson K, Lal L, Brew BJ NeuroAIDS in the Asia Pacific Region. J Neurovirol 2008, 14:465-473.
14. Heaton RK, Cysique LA, Jin H, et al. Neurobehavioral effects of human immunodeficiency virus infection among former plasma donors in rural China. J Neurovirol 2008, 14:536-549.
15. McArthur JC HIV dementia: an evolving disease. J Neuroimmunol 2004, 157:3-10.
16. Robertson KR, Smurzynski M, Parsons TD, et al. The prevalence and incidence of neurocognitive impairment in the HAART era. AIDS 2007, 21:1915-1921.
17. Sacktor N, Lyles RH, Skolasky R, et al. HIV-associated neurologic disease incidence changes:: Multicenter AIDS Cohort Study, 1990-1998. Neurology 2001, 56:257-260.
18. Woods SP, Moore DJ, Weber E, Grant I Cognitive neuropsychology of HIV-associated neurocognitive disorders. Neuropsychol Rev 2009, 19:152-168.
19. Cysique LA, Maruff P, Brew BJ Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/AIDS) patients across pre- and post-highly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004, 10:350-357.
20. Simioni S, Cavassini M, Annoni JM, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010, 24:1243-1250.
21. Garvey L, Surendrakumar V, Winston A Low rates of neurocognitive impairment are observed in neuro-asymptomatic HIV-infected subjects on effective antiretroviral therapy. HIV Clin Trials 2011, 12:333-338.
22. Crum-Cianflone NF, Moore DJ, Letendre S, et al. Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons. Neurology 2013, 80:371-379.
23. Gorman AA, Foley JM, Ettenhofer ML, Hinkin CH, van Gorp WG Functional Consequences of HIV-Associated Neuropsychological Impairment. Neuropsychol Rev 2009, 19:186-203.
24. Grant I, Franklin DR, Deutsch R, et al. Asymptomatic HIV-associated neurocognitive impairment increases risk for symptomatic decline. Neurology 2014, 82:2055-2062.
25. Brew BJ, Pemberton L, Cunningham P, Law MG Levels of human immunodeficiency virus type 1 RNA in cerebrospinal fluid correlate with AIDS dementia stage. J Infect Dis 1997, 175:963-966.
26. Ellis RJ, Moore DJ, Childers ME, et al. Progression to neuropsychological impairment in human immunodeficiency virus infection predicted by elevated cerebrospinal fluid levels of human immunodeficiency virus RNA. Arch Neurol 2002, 59:923-928.
27. Ho DD, Rota TR, Schooley RT, et al. Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med 1985, 313:1493-1497.
28. Sonnerborg AB, Ehrnst AC, Bergdahl SK, Pehrson PO, Skoldenberg BR, Strannegard OO HIV isolation from cerebrospinal fluid in relation to immunological deficiency and neurological symptoms. AIDS 1988, 2:89-93.
29. Canestri A, Lescure FX, Jaureguiberry S, et al. Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010, 50:773-778.
30. Peluso MJ, Ferretti F, Peterson J, et al. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load. AIDS 2012, 26:1765-1774.
31. Cunningham PH, Smith DG, Satchell C, Cooper DA, Brew B Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 2000, 14:1949-1954.
32. Venturi G, Catucci M, Romano L, et al. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 2000, 181:740-745.
33. Strain MC, Letendre S, Pillai SK, et al. Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol 2005, 79:1772-1788.
34. Letendre S, Marquie-Beck J, Capparelli E, et al. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008, 65:65-70.
35. Cysique LA, Waters EK, Brew BJ Central nervous system antiretroviral efficacy in HIV infection: a qualitative and quantitative review and implications for future research. BMC Neurol 2011, 11:148.
36. Robertson K, Liner J, Meeker RB Antiretroviral neurotoxicity. J Neurovirol 2012, 18:388-399.
37. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004, 78:10133-10148.
38. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. Acquir Immune Defic Syndr 2007, 45:174-182.
39. Giancola ML, Lorenzini P, Balestra P, et al. Neuroactive antiretroviral drugs do not influence neurocognitive performance in less advanced HIV-infected patients responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006, 41:332-337.
40. Smurzynski M, Wu K, Letendre S, et al. Effects of central nervous system antiretroviral penetration on cognitive functioning in the ALLRT cohort. AIDS 2011, 25:357-365.
41. Assessment, diagnosis, and treatment of HIV-associated neurocognitive disorder: a consensus report of the mind exchange program. Clin Infect Dis 2013, 56:1004-1017. Mind Exchange Working Group.
42. Standards of care for people living with HIV British HIV Association, (accessed Jan 3, 2014). http://www.bhiva.org/documents/Standards-of-care/BHIVAStandardsA4.pdf.
43. Guidelines version 7.02 European AIDS Clinical Society, (accessed July 3, 2014). http://www.eacsociety.org/Portals/0/140601_EACEN7.02.pdf.
44. Shikuma CM, Nakamoto B, Shiramizu B, et al. Antiretroviral monocyte efficacy score linked to cognitive impairment in HIV. Antivir Ther 2012, 17:1233-1242.
45. Brew BJ, Letendre SL Biomarkers of HIV related central nervous system disease. Int Rev Psychiatry 2008, 20:73-88.
46. Wright EJ, Grund B, Robertson K, et al. Cardiovascular risk factors associated with lower baseline cognitive performance in HIV-positive persons. Neurology 2010, 75:864-873.
47. Samaras K, Wand H, Law M, Emery S, Cooper D, Carr A Prevalence of metabolic syndrome in HIV-infected patients receiving highly active antiretroviral therapy using International Diabetes Foundation and Adult Treatment Panel III criteria: associations with insulin resistance, disturbed body fat compartmentalization, elevated C-reactive protein, and [corrected] hypoadiponectinemia. Diabetes Care 2007, 30:113-119.
48. Fletcher NF, McKeating JA Hepatitis C virus and the brain. J Viral Hepat 2012, 19:301-306.
49. Perry W, Carlson MD, Barakat F, et al. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS 2005, 19(suppl 3):79-84.
50. Ciccarelli N, Fabbiani M, Grima P, et al. Comparison of cognitive performance in HIV or HCV mono-infected and HIV-HCV co-infected patients. Infection 2013, 41:1103-1109.
51. Rippeth JD, Heaton RK, Carey CL, et al. Methamphetamine dependence increases risk of neuropsychological impairment in HIV infected persons. J Int Neuropsychol Soc 2004, 10:1-14.
52. Jernigan TL, Gamst AC, Archibald SL, et al. Effects of methamphetamine dependence and HIV infection on cerebral morphology. Am J Psychiatry 2005, 162:1461-1472.
53. Valcour V, Shikuma C, Shiramizu B, et al. Age, apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV Cohort. J Neuroimmunol 2004, 157:197-202.
54. Morgan EE, Woods SP, Letendre SL, et al. Apolipoprotein E4 genotype does not increase risk of HIV-associated neurocognitive disorders. J Neurovirol 2013, 19:150-156.
55. Canizares S, Cherner M, Ellis RJ HIV and aging: effects on the central nervous system. Semin Neurol 2014, 34:27-34.
56. Atkinson JH, Heaton RK, Patterson TL, et al. Two-year prospective study of major depressive disorder in HIV-infected men. J Affect Disord 2008, 108:225-234.
57. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69:1789-1799.
58. Heaton RK, Marcotte TD, Mindt MR, et al. The impact of HIV-associated neuropsychological impairment on everyday functioning. J Int Neuropsychol Soc 2004, 10:317-331.
59. Lawton MP, Brody EM Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 1969, 9:179-186.
60. Robertson K, Jiang H, Kumwenda J, et al. Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis 2012, 55:868-876.
61. Winston A, Arenas-Pinto A, Stohr W, et al. Neurocognitive function in HIV infected patients on antiretroviral therapy. PLoS One 2013, 8:e61949.
62. Sacktor N, Nakasujja N, Robertson K, Clifford DB HIV-associated cognitive impairment in sub-Saharan Africa--the potential effect of clade diversity. Nat Clin Pract Neurol 2007, 3:436-443.
63. Cysique LA, Letendre SL, Ake C, et al. Incidence and nature of cognitive decline over 1 year among HIV-infected former plasma donors in China. AIDS 2010, 24:983-990.
64. Gisslen M, Price RW, Nilsson S The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence?. BMC Infect Dis 2011, 11:356.
65. Cherner M, Masliah E, Ellis RJ, et al. Neurocognitive dysfunction predicts postmortem findings of HIV encephalitis. Neurology 2002, 59:1563-1567.
66. Wilson JM, Jungner YG Principles and practice of mass screening for disease. Bol Oficina Sanit Panam 1968, 65:281-393.
67. Winston A, Duncombe C, Li PC, et al. Does choice of combination antiretroviral therapy (cART) alter changes in cerebral function testing after 48 weeks in treatment-naive, HIV-1-infected individuals commencing cART? A randomized, controlled study. Clin Infect Dis 2010, 50:920-929.
68. Marcondes MC, Flynn C, Huitron-Rezendiz S, Watry DD, Zandonatti M, Fox HS Early antiretroviral treatment prevents the development of central nervous system abnormalities in simian immunodeficiency virus-infected rhesus monkeys. AIDS 2009, 23:1187-1195.
69. Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis 2011, 52:793-800.
70. Letendre S, McClemon D, Ellis R, et al. Persistent HIV in the central nervous system during treatment is associated with worse ART penetration and cognitive impairment. 16th Conference on Retroviruses and Opportunistic Infections (CROI 2009; Montreal, Canada; 2009. 484b.
71. Perez Valero I, Letendre S, Ellis R, et al. Prevalence and risk factors for HIV CSF viral escape: results from the CHARTER and HNRP cohorts. J Int AIDS Soc 2012, 15(suppl 4):18189.
72. Nath A, Geiger J Neurobiological aspects of human immunodeficiency virus infection: neurotoxic mechanisms. Prog Neurobiol 1998, 54:19-33.
73. Tyler KL, McArthur JC Through a glass, darkly: cerebrospinal fluid viral load measurements and the pathogenesis of human immunodeficiency virus infection of the central nervous system. Arch Neurol 2002, 59:909-912.
74. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004, 63:2084-2090.
75. McClernon D, Letendre S, Benjamin R Low-level HIV-1 viral load monitoring in cerebral spinal fluid: possible correlation to antiviral drug penetration 2007, European AIDS Clinical Society (EACS), Madrid, Spain, P611/101.
76. Wiley CA, Soontornniyomkij V, Radhakrishnan L, et al. Distribution of brain HIV load in AIDS. Brain Pathol 1998, 8:277-284.
77. McArthur JC, McClernon DR, Cronin MF, et al. Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol 1997, 42:689-698.
78. Cole MA, Margolick JB, Cox C, et al. Longitudinally preserved psychomotor performance in long-term asymptomatic HIV-infected individuals. Neurology 2007, 69:2213-2220.
79. Marcotte TD, Deutsch R, Michael BD, et al. A concise panel of biomarkers identifies neurocognitive functioning changes in HIV-infected individuals. J Neuroimmune Pharmacol 2013, 8:1123-1135.
80. Saksena NK, Potter SJ Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev 2003, 5:3-18.
81. Harrington PR, Schnell G, Letendre SL, et al. Cross-sectional characterization of HIV-1 env compartmentalization in cerebrospinal fluid over the full disease course. AIDS 2009, 23:907-915.
82. Ritola K, Robertson K, Fiscus SA, Hall C, Swanstrom R Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol 2005, 79:10830-10834.
83. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med 2012, 13(suppl 2):1-85.
84. Desplats P, Dumaop W, Smith D, et al. Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology 2013, 80:1415-1423.
85. Liner KJ, Ro MJ, Robertson KR HIV, antiretroviral therapies, and the brain. Curr HIV/AIDS Rep 2010, 7:85-91.
86. Letendre S, Fitzsimons C, Ellis RJ, et al. Correlates of CSF Viral Loads in 1,221 Volunteers of the CHARTER Cohort. 17th Conference on Retroviruses and Opportunistic Infections; San Fransisco, CA, USA; 2010. 172.
87. Ellis RJ, Letendre S, Vaida F, et al. Randomized trial of central nervous system-targeted antiretrovirals for HIV-associated neurocognitive disorder. Clin Infect Dis 2014, 58:1015-1022.
88. Antinori A, Perno CF, Giancola ML, et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005, 41:1787-1793.
89. Vissers M, Stelma FF, Koopmans PP Could differential virological characteristics account for ongoing viral replication and insidious damage of the brain during HIV 1 infection of the central nervous system?. J Clin Virol 2010, 49:231-238.
90. Soulie C, Fourati S, Lambert-Niclot S, et al. HIV genetic diversity between plasma and cerebrospinal fluid in patients with HIV encephalitis. AIDS 2010, 24:2412-2414.
91. Palmer AM The role of the blood-CNS barrier in CNS disorders and their treatment. Neurobiol Dis 2010, 37:3-12.
92. Anthonypillai C, Sanderson RN, Gibbs JE, Thomas SA The distribution of the HIV protease inhibitor, ritonavir, to the brain, cerebrospinal fluid, and choroid plexuses of the guinea pig. J Pharmacol Exp Ther 2004, 308:912-920.
93. Gibbs JE, Gaffen Z, Thomas SA Nevirapine uptake into the central nervous system of the Guinea pig: an in situ brain perfusion study. J Pharmacol Exp Ther 2006, 317:746-751.
94. Aquaro S, Calio R, Balzarini J, Bellocchi MC, Garaci E, Perno CF Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir. Antiviral Res 2002, 55:209-225.
95. Perno CF, Svicher V, Schols D, Pollicita M, Balzarini J, Aquaro S Therapeutic strategies towards HIV-1 infection in macrophages. Antiviral Res 2006, 71:293-300.
96. Sidtis JJ, Gatsonis C, Price RW, et al. Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol 1993, 33:343-349.
97. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998, 101:289-294.
98. Perez-Valero I, Gonzalez-Baeza A, Estebanez M, et al. Neurocognitive impairment in patients treated with protease inhibitor monotherapy or triple drug antiretroviral therapy. PLoS One 2013, 8:e69493.
99. Liner J, Meeker R, Robertson K. CNS toxicity of antiretroviral drugs. 17th Conference on Retroviruses and Opportunistic Infections; San Fransisco, CA, USA; 2010. 435.
100. Tovar YRLB, Bumpus NN, Pomerantz D, et al. Dendritic spine injury induced by the 8-hydroxy metabolite of efavirenz. J Pharmacol Exp Ther 2012, 343:696-703.
101. Lescure F, Ameil C, Gray F, et al. Lymphocytes T8 infiltrative encephalitis: a new form of neurological complication in HIV infection. XVIII International AIDS Conference; Vienna, Austria; July 18-23 2010. WEAB0303.
102. Johnson T, Nath A Immune reconstitution inflammatory syndrome and the central nervous system. Curr Opin Neurol 2011, 24:284-290.
103. Thames AD, Kim MS, Becker BW, et al. Medication and finance management among HIV-infected adults: the impact of age and cognition. J Clin Exp Neuropsychol 2011, 33:200-209.
104. Holt JL, Kraft-Terry SD, Chang L Neuroimaging studies of the aging HIV-1-infected brain. J Neurovirol 2012, 18:291-302.
105. Ances BM, Benzinger TL, Christensen JJ, et al. 11C-PiB imaging of human immunodeficiency virus-associated neurocognitive disorder. Arch Neurol 2012, 69:72-77.
106. Garvey L, Winston A, Sabin C, Study ftUCC. Do antiretroviral combination therapies with greater central nervous system (CNS) penetration prevent the development of CNS opportunistic diseases? 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; 2010. 427.
107. Joska JA, Gouse H, Paul RH, Stein DJ, Flisher AJ Does highly active antiretroviral therapy improve neurocognitive function? A systematic review. J Neurovirol 2010, 16:101-114.
108. Robertson KR, Robertson WT, Ford S, et al. Highly active antiretroviral therapy improves neurocognitive functioning. J Acquir Immune Defic Syndr 2004, 36:562-566.
109. Cysique LA, Vaida F, Letendre S, et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009, 73:342-348.
110. Tozzi V, Balestra P, Galgani S, et al. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment. AIDS 1999, 13:1889-1897.
111. Peterson J, Lee E, Hecht F, Price R, Robertson K, Spudich S. Neurocognitive Performance during Primary HIV-1 Infection. 17th Conference on Retroviruses and Opportunistic Infections; San Francisco, CA, USA; 2010. 424.